SELECTIVE GLYCOSIDASE INHIBITORS AND THEIR APPLICATION Russian patent published in 2017 - IPC C07H9/06 C07D513/04 A61K31/7056 C12Q1/34 C12Q1/37 

FIELD: pharmacology.

SUBSTANCE: invention relates to compound of formula (I) or to pharmaceutically acceptable salt thereof, wherein R¹ and R² independently represent H or F; R³ represents OR⁵ and R⁴ represents H, or R³ represents H and R⁴ represents OR⁵; each of R⁵ represents H; R⁶ represents H or OR⁵; R⁷ is selected from the group consisting of H and C_1-8-alkyl; R⁸ is selected from the group consisting of C_1-8-alkyl optionally substituted with 1-3 fluorine atoms; and each of R⁹ is independently selected from the group consisting of H, C_1-6-alkyl, or two groups of R⁹ are linked together with the nitrogen atom to which they are attached to form a 4-membered ring containing 3 carbon atoms. Compounds of formula (I) are intended to produce a drug or a pharmaceutical composition having glycoprotein 2-acetamido-2-deoxy-β-D-glucopyranosidase (O-GlcNAcase) inhibitory activity. The invention also relates to a method of glycoprotein 2-acetamido-2-deoxy-β-D-glucopyranosidase (O-GlcNAcase) selective inhibition in a subject in need thereof, comprising injection of an effective amount of the compound of formula (I) or pharmaceutically acceptable salt thereof to the subject. Compounds of formula (I) are used to treat diseases mediated by glycoprotein 2-acetamido-2-deoxy-β-D-glucopyranosidase (O-GlcNAcase) inhibition.

EFFECT: selective glycosidase inhibitors.

22 cl, 5 tbl, 49 ex